{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:36:32Z","timestamp":1758044192525,"version":"3.44.0"},"reference-count":149,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780128164228"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/b978-0-12-816422-8.00008-8","type":"book-chapter","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T05:44:34Z","timestamp":1598593474000},"page":"179-213","source":"Crossref","is-referenced-by-count":0,"title":["Targeting chromatin remodelers in urological tumors"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-1391","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Lobo","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-4666","authenticated-orcid":false,"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2051415816674103","article-title":"The epidemiology of urological cancer 2001\u20132013","volume":"10","author":"Kockelbergh","year":"2017","journal-title":"J Clin Urol"},{"issue":"6","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0015","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/bju.13875","article-title":"Association of Human Development Index with global bladder, kidney, prostate and testis cancer incidence and mortality","volume":"120","author":"Greiman","year":"2017","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0020","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3941","article-title":"Histone exchange, chromatin structure and the regulation of transcription","volume":"16","author":"Venkatesh","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0025","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tig.2015.10.007","article-title":"Lateral thinking: how histone modifications regulate gene expression","volume":"32","author":"Lawrence","year":"2016","journal-title":"Trends Genet"},{"issue":"2","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41556-018-0258-1","article-title":"Chromatin regulatory mechanisms and therapeutic opportunities in cancer","volume":"21","author":"Valencia","year":"2019","journal-title":"Nat Cell Biol"},{"year":"2018","series-title":"Global Cancer Observatory: Cancer Tomorrow","author":"Ferlay","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0035"},{"issue":"6","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0040","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1634\/theoncologist.2016-0435","article-title":"Current clinical practice guidelines for the treatment of renal cell carcinoma: a systematic review and critical evaluation","volume":"22","author":"Bamias","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/B978-0-12-816422-8.00008-8_bb0045","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1975\u20132016), National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, Based on the November 2018 submission, n.d."},{"issue":"5","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0050","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2214\/AJR.06.0920","article-title":"Renal pseudotumors","volume":"188","author":"Bhatt","year":"2007","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0055","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4103\/0971-3026.195773","article-title":"Solid renal masses in adults","volume":"26","author":"Mittal","year":"2016","journal-title":"Indian J Radiol Imaging"},{"issue":"1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0065","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1016\/j.celrep.2018.06.032","article-title":"The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma","volume":"23","author":"Ricketts","year":"2018","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11523-016-0463-4","article-title":"Resistance to targeted therapies in renal cancer: the importance of changing the mechanism of action","volume":"12","author":"Duran","year":"2017","journal-title":"Target Oncol"},{"issue":"7","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0075","doi-asserted-by":"crossref","first-page":"658","DOI":"10.4161\/cbt.10.7.13247","article-title":"Signaling pathways in renal cell carcinoma","volume":"10","author":"Banumathy","year":"2010","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0080","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/CCO.0000000000000186","article-title":"Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology","volume":"27","author":"Su","year":"2015","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0085","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMe068263","article-title":"Renal-cell carcinoma\u2014molecular pathways and therapies","volume":"356","author":"Brugarolas","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0090","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1053\/j.seminoncol.2006.06.001","article-title":"Molecular pathways in renal cell carcinoma\u2014rationale for targeted treatment","volume":"33","author":"Kim","year":"2006","journal-title":"Semin Oncol"},{"issue":"suppl 1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0095","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/eci.12360","article-title":"New insights on chromatin modifiers and histone post-translational modifications in renal cell tumours","volume":"45","author":"Vieira-Coimbra","year":"2015","journal-title":"Eur J Clin Invest"},{"issue":"7279","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0100","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature08672","article-title":"Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes","volume":"463","author":"Dalgliesh","year":"2010","journal-title":"Nature"},{"issue":"31","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0105","doi-asserted-by":"crossref","first-page":"32161","DOI":"10.18632\/oncotarget.5147","article-title":"Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma","volume":"6","author":"Piva","year":"2015","journal-title":"Oncotarget"},{"issue":"7471","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0110","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0115","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.neo.2018.12.006","article-title":"Expression and mutation patterns of PBRM1, BAP1 and SETD2 mirror specific evolutionary subtypes in clear cell renal cell carcinoma","volume":"21","author":"Bihr","year":"2019","journal-title":"Neoplasia"},{"issue":"45","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0120","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002004","article-title":"Decreased expression of SETD2 predicts unfavorable prognosis in patients with nonmetastatic clear-cell renal cell carcinoma","volume":"94","author":"Liu","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0125","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.juro.2016.06.010","article-title":"Prognostic value of SETD2 expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors","volume":"196","author":"Wang","year":"2016","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0130","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1074\/mcp.RA118.000957","article-title":"Integrated genomic and proteomic analyses reveal novel mechanisms of the methyltransferase SETD2 in renal cell carcinoma development","volume":"18","author":"Li","year":"2019","journal-title":"Mol Cell Proteomics"},{"issue":"6","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0135","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.neo.2016.04.005","article-title":"Functional studies on primary tubular epithelial cells indicate a tumor suppressor role of SETD2 in clear cell renal cell carcinoma","volume":"18","author":"Li","year":"2016","journal-title":"Neoplasia"},{"issue":"6","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0140","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.18632\/oncotarget.2926","article-title":"miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma","volume":"6","author":"Xiang","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0145","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1158\/0008-5472.CAN-17-3460","article-title":"SETD2 haploinsufficiency for microtubule methylation is an early driver of genomic instability in renal cell carcinoma","volume":"78","author":"Chiang","year":"2018","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0150","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/15592294.2015.1103578","article-title":"Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication","volume":"10","author":"Pires-Luis","year":"2015","journal-title":"Epigenetics"},{"issue":"23","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0155","doi-asserted-by":"crossref","first-page":"38044","DOI":"10.18632\/oncotarget.16765","article-title":"Functional and therapeutic significance of EZH2 in urological cancers","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0160","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.bbrc.2012.05.035","article-title":"The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells","volume":"422","author":"Sakurai","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0165","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.5858\/arpa.2012-0525-OA","article-title":"Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature","volume":"137","author":"Xu","year":"2013","journal-title":"Arch Pathol Lab Med"},{"issue":"11","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081484","article-title":"Prognostic value of EZH2 expression and activity in renal cell carcinoma: a prospective study","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0175","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/bju.12702","article-title":"Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma","volume":"117","author":"Liu","year":"2016","journal-title":"BJU Int"},{"issue":"9","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0180","doi-asserted-by":"crossref","first-page":"7159","DOI":"10.1007\/s13277-015-3417-z","article-title":"Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas","volume":"36","author":"Wang","year":"2015","journal-title":"Tumour Biol"},{"issue":"1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0185","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/1541-7786.MCR-17-0636","article-title":"Integrative epigenetic and gene expression analysis of renal tumor progression to metastasis","volume":"17","author":"Nam","year":"2019","journal-title":"Mol Cancer Res"},{"issue":"9","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0190","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1158\/1078-0432.CCR-04-1155","article-title":"Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model","volume":"11","author":"Touma","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"8B","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0195","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/j.1582-4934.2008.00436.x","article-title":"The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo","volume":"13","author":"Jones","year":"2009","journal-title":"J Cell Mol Med"},{"issue":"1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0200","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1158\/1078-0432.CCR-09-1385","article-title":"Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels","volume":"16","author":"Mahalingam","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0205","first-page":"3161","article-title":"HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells","volume":"32","author":"Kim","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/B978-0-12-816422-8.00008-8_bb0210","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2490-14-71","article-title":"Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells","volume":"14","author":"Sato","year":"2014","journal-title":"BMC Urol"},{"issue":"1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0215","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.canlet.2012.05.003","article-title":"Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells","volume":"324","author":"Juengel","year":"2012","journal-title":"Cancer Lett"},{"issue":"17","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0220","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","article-title":"Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma","volume":"23","author":"Orillion","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030815","article-title":"Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models","volume":"7","author":"Shen","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0230","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1159\/000494185","article-title":"Bromodomain-containing protein 4 (BRD4) inhibition sensitizes palomid 529-induced anti-renal cell carcinoma cell activity in vitro and in vivo","volume":"50","author":"Xing","year":"2018","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0235","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/s41598-018-19199-z","article-title":"The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection","volume":"8","author":"Wong","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0240","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","article-title":"Economic burden of bladder cancer across the European Union","volume":"69","author":"Leal","year":"2016","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0245","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/B978-0-12-816422-8.00008-8_bb0250","doi-asserted-by":"crossref","first-page":"17022","DOI":"10.1038\/nrdp.2017.22","article-title":"Bladder cancer","volume":"3","author":"Sanli","year":"2017","journal-title":"Nat Rev Dis Primers"},{"year":"2016","series-title":"WHO Classification of Tumours of the Urinary System and Male Genital Organs","author":"Moch","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0255"},{"issue":"1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0260","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","article-title":"Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification","volume":"242","author":"Sjodahl","year":"2017","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0265","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0270","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"174","author":"Robertson","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0275","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.eururo.2018.11.014","article-title":"MSH2 expression and resistance to cisplatin in muscle-invasive bladder cancer: a mix of progress and challenges","volume":"75","author":"Henrique","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0280","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1586\/era.11.201","article-title":"Molecular mechanisms of cisplatin resistance in bladder cancer","volume":"12","author":"Drayton","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0285","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000355467","article-title":"Alterations of global histone H3K9 and H3K27 methylation levels in bladder cancer","volume":"93","author":"Ellinger","year":"2014","journal-title":"Urol Int"},{"issue":"1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0290","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12935-014-0149-x","article-title":"EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cells","volume":"15","author":"Cui","year":"2015","journal-title":"Cancer Cell Int"},{"key":"10.1016\/B978-0-12-816422-8.00008-8_bb0295","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41401-018-0205-5","article-title":"Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells","volume":"40","author":"Cao","year":"2019","journal-title":"Acta Pharmacol Sin"},{"issue":"9","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138390","article-title":"G9a inhibition induces autophagic cell death via AMPK\/mTOR pathway in bladder transitional cell carcinoma","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/B978-0-12-816422-8.00008-8_bb0305","doi-asserted-by":"crossref","first-page":"8293","DOI":"10.1038\/srep08293","article-title":"Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation","volume":"5","author":"Chen","year":"2015","journal-title":"Sci Rep"},{"issue":"54","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0310","doi-asserted-by":"crossref","first-page":"92032","DOI":"10.18632\/oncotarget.20734","article-title":"Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K\/Akt signaling pathways","volume":"8","author":"Imai-Sumida","year":"2017","journal-title":"Oncotarget"},{"issue":"35","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0315","doi-asserted-by":"crossref","first-page":"37335","DOI":"10.18632\/oncotarget.6135","article-title":"Honokiol inhibits bladder tumor growth by suppressing EZH2\/miR-143 axis","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/B978-0-12-816422-8.00008-8_bb0320","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jprot.2017.01.013","article-title":"The impact of cruciferous vegetable isothiocyanates on histone acetylation and histone phosphorylation in bladder cancer","volume":"156","author":"Abbaoui","year":"2017","journal-title":"J Proteomics"},{"issue":"5","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0325","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ijc.20634","article-title":"Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo","volume":"113","author":"Canes","year":"2005","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0330","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1442-2042.2006.01344.x","article-title":"Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest","volume":"13","author":"Li","year":"2006","journal-title":"Int J Urol"},{"key":"10.1016\/B978-0-12-816422-8.00008-8_bb0335","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1479-5876-5-49","article-title":"The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo","volume":"5","author":"Buckley","year":"2007","journal-title":"J Transl Med"},{"key":"10.1016\/B978-0-12-816422-8.00008-8_bb0340","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2490-12-21","article-title":"Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression","volume":"12","author":"Byler","year":"2012","journal-title":"BMC Urol"},{"issue":"6","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0345","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/j.juro.2011.07.107","article-title":"Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro","volume":"186","author":"Deb","year":"2011","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0350","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/mc.22117","article-title":"Phenotypic impact of deregulated expression of class I histone deacetylases in urothelial cell carcinoma of the bladder","volume":"54","author":"Junqueira-Neto","year":"2015","journal-title":"Mol Carcinog"},{"issue":"3","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0355","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.juro.2010.10.034","article-title":"The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line","volume":"185","author":"Yoon","year":"2011","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0360","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.radonc.2013.06.021","article-title":"Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression","volume":"108","author":"Groselj","year":"2013","journal-title":"Radiother Oncol"},{"issue":"11","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0365","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1158\/0008-5472.CAN-16-3232","article-title":"E3 ligase cIAP2 mediates downregulation of MRE11 and radiosensitization in response to HDAC inhibition in bladder cancer","volume":"77","author":"Nicholson","year":"2017","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0370","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.tranon.2019.02.001","article-title":"Metformin augments panobinostat's anti-bladder cancer activity by activating AMP-activated protein kinase","volume":"12","author":"Okubo","year":"2019","journal-title":"Transl Oncol"},{"issue":"8","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0375","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.nano.2013.05.017","article-title":"Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer","volume":"9","author":"Martin","year":"2013","journal-title":"Nanomedicine"},{"issue":"12","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0380","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.7150\/jca.19967","article-title":"Silencing of HJURP induces dysregulation of cell cycle and ROS metabolism in bladder cancer cells via PPARgamma-SIRT1 feedback loop","volume":"8","author":"Cao","year":"2017","journal-title":"J Cancer"},{"key":"10.1016\/B978-0-12-816422-8.00008-8_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-017-0434-3","article-title":"Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines","volume":"10","author":"Holscher","year":"2018","journal-title":"Clin Epigenetics"},{"key":"10.1016\/B978-0-12-816422-8.00008-8_bb0390","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0395","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/1758834017719215","article-title":"Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications","volume":"9","author":"Terada","year":"2017","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0400","first-page":"125","article-title":"Classification of prostatic carcinomas","volume":"50","author":"Gleason","year":"1966","journal-title":"Cancer Chemother Rep"},{"issue":"3","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0405","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A contemporary prostate cancer grading system: a validated alternative to the Gleason score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0410","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/bjc.2016.86","article-title":"Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome","volume":"114","author":"Berney","year":"2016","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0415","doi-asserted-by":"crossref","first-page":"161.e7","DOI":"10.1016\/j.urolonc.2017.10.028","article-title":"High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer","volume":"36","author":"Lobo","year":"2018","journal-title":"Urol Oncol"},{"issue":"12","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0420","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/bies.20676","article-title":"Androgen signaling and its interactions with other signaling pathways in prostate cancer","volume":"29","author":"Kaarbo","year":"2007","journal-title":"Bioessays"},{"issue":"11","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0425","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nrc1474","article-title":"The emerging roles of human tissue kallikreins in cancer","volume":"4","author":"Borgono","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0430","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/2159-8290.CD-13-1010","article-title":"The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis","volume":"4","author":"Lucas","year":"2014","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0435","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4172\/1948-5956.1000119","article-title":"TMPRSS2-ERG fusion gene expression in prostate tumor cells and its clinical and biological significance in prostate cancer progression","volume":"4","author":"St John","year":"2012","journal-title":"J Cancer Sci Ther"},{"key":"10.1016\/B978-0-12-816422-8.00008-8_bb0440","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jsbmb.2016.07.006","article-title":"Dissecting major signaling pathways in prostate cancer development and progression: mechanisms and novel therapeutic targets","volume":"166","author":"Ramalingam","year":"2017","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0445","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/1534735404270757","article-title":"Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy","volume":"3","author":"McCarty","year":"2004","journal-title":"Integr Cancer Ther"},{"issue":"1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0450","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s10020-018-0035-4","article-title":"The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer","volume":"24","author":"Mandel","year":"2018","journal-title":"Mol Med"},{"issue":"18","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0455","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1073\/pnas.1804205115","article-title":"LSD1: a single target to combat lineage plasticity in lethal prostate cancer","volume":"115","author":"Ellis","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0460","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11255-015-0915-2","article-title":"Relationship between LSD1 expression and E-cadherin expression in prostate cancer","volume":"47","author":"Wang","year":"2015","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0465","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bbrc.2015.09.164","article-title":"Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo","volume":"467","author":"Wang","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0470","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.molonc.2013.01.003","article-title":"The lysine specific demethylase-1 (LSD1\/KDM1A) regulates VEGF-A expression in prostate cancer","volume":"7","author":"Kashyap","year":"2013","journal-title":"Mol Oncol"},{"issue":"4","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0475","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/pcan.2016.21","article-title":"Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells","volume":"19","author":"Gupta","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0480","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1021\/acs.jmedchem.7b00133","article-title":"A Rhodium(III)-based inhibitor of lysine-specific histone demethylase 1 as an epigenetic modulator in prostate cancer cells","volume":"60","author":"Yang","year":"2017","journal-title":"J Med Chem"},{"issue":"18","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0485","doi-asserted-by":"crossref","first-page":"E4179","DOI":"10.1073\/pnas.1719168115","article-title":"LSD1 activates a lethal prostate cancer gene network independently of its demethylase function","volume":"115","author":"Sehrawat","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"16","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0490","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/pros.23235","article-title":"Metformin elicits antitumor effects and downregulates the histone methyltransferase multiple myeloma SET domain (MMSET) in prostate cancer cells","volume":"76","author":"White-Al Habeeb","year":"2016","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0495","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2017.28","article-title":"Metformin inhibits SUV39H1-mediated migration of prostate cancer cells","volume":"6","author":"Yu","year":"2017","journal-title":"Oncogenesis"},{"issue":"3","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0500","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41389-019-0122-6","article-title":"Dihydroartemisinin inhibits prostate cancer via JARID2\/miR-7\/miR-34a-dependent downregulation of Axl","volume":"8","author":"Paccez","year":"2019","journal-title":"Oncogenesis"},{"key":"10.1016\/B978-0-12-816422-8.00008-8_bb0505","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/mc.23003","article-title":"Green tea-induced epigenetic reactivation of tissue inhibitor of matrix metalloproteinase-3 suppresses prostate cancer progression through histone-modifying enzymes","volume":"58","author":"Deb","year":"2019","journal-title":"Mol Carcinog"},{"issue":"11","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0510","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.3390\/nu10111784","article-title":"Rosmarinic acid, a component of rosemary tea, induced the cell cycle arrest and apoptosis through modulation of HDAC2 expression in prostate cancer cell lines","volume":"10","author":"Jang","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/B978-0-12-816422-8.00008-8_bb0515","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1471-2407-12-145","article-title":"Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells","volume":"12","author":"Phillip","year":"2012","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0520","doi-asserted-by":"crossref","first-page":"nzy002","DOI":"10.1093\/cdn\/nzy002","article-title":"Broccoli sprouts delay prostate cancer formation and decrease prostate cancer severity with a concurrent decrease in HDAC3 protein expression in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice","volume":"2","author":"Beaver","year":"2018","journal-title":"Curr Dev Nutr"},{"issue":"11","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0525","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/carcin\/bgv137","article-title":"Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters","volume":"36","author":"Melling","year":"2015","journal-title":"Carcinogenesis"},{"issue":"6113","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0530","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1227604","article-title":"EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent","volume":"338","author":"Xu","year":"2012","journal-title":"Science"},{"issue":"5","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0535","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/cam4.289","article-title":"Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer","volume":"3","author":"Paller","year":"2014","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0540","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10637-017-0529-x","article-title":"Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer","volume":"36","author":"Park","year":"2018","journal-title":"Invest New Drugs"},{"issue":"11","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0545","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/cam4.1209","article-title":"Targeting MTA1\/HIF-1alpha signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression","volume":"6","author":"Butt","year":"2017","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0550","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13046-018-0810-7","article-title":"PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1\/BRCA1 DNA damage repair complex in prostate cancer cells","volume":"37","author":"Yin","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0555","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1021\/acsomega.6b00126","article-title":"Prostate-specific membrane antigen targeted polymersomes for delivering mocetinostat and docetaxel to prostate cancer cell spheroids","volume":"1","author":"Karandish","year":"2016","journal-title":"ACS Omega"},{"key":"10.1016\/B978-0-12-816422-8.00008-8_bb0560","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1038\/s41388-018-0356-3","article-title":"MacroH2A1.2 inhibits prostate cancer-induced osteoclastogenesis through cooperation with HP1alpha and H1.2","volume":"37","author":"Kim","year":"2018","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0565","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41467-017-01393-8","article-title":"Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer","volume":"8","author":"Valdes-Mora","year":"2017","journal-title":"Nat Commun"},{"issue":"97","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0570","doi-asserted-by":"crossref","first-page":"37054","DOI":"10.18632\/oncotarget.26457","article-title":"Metformin alters H2A.Z dynamics and regulates androgen dependent prostate cancer progression","volume":"9","author":"Tyagi","year":"2018","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0575","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.18632\/oncotarget.1237","article-title":"Regulation of histone H2A.Z expression is mediated by sirtuin 1 in prostate cancer","volume":"4","author":"Baptista","year":"2013","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0580","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/j.celrep.2017.05.049","article-title":"Androgen receptor deregulation drives bromodomain-mediated chromatin alterations in prostate cancer","volume":"19","author":"Urbanucci","year":"2017","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0585","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.celrep.2017.12.078","article-title":"BRD4 promotes DNA repair and mediates the formation of TMPRSS2-ERG gene rearrangements in prostate cancer","volume":"22","author":"Li","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/B978-0-12-816422-8.00008-8_bb0590","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.humpath.2018.07.016","article-title":"Testicular germ cell tumors: revisiting a series in light of the new WHO classification and AJCC staging systems, focusing on challenges for pathologists","volume":"82","author":"Lobo","year":"2018","journal-title":"Hum Pathol"},{"issue":"2\u20134","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0595","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1387\/ijdb.130017ll","article-title":"Role of epigenetics in the etiology of germ cell cancer","volume":"57","author":"Van Der Zwan","year":"2013","journal-title":"Int J Dev Biol"},{"key":"10.1016\/B978-0-12-816422-8.00008-8_bb0600","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.semcancer.2014.07.003","article-title":"An oncofetal and developmental perspective on testicular germ cell cancer","volume":"29","author":"Rijlaarsdam","year":"2014","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0605","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3390\/ijms20020258","article-title":"Human germ cell tumors are developmental cancers: impact of epigenetics on pathobiology and clinic","volume":"20","author":"Lobo","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0610","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nrc1568","article-title":"Testicular germ-cell tumours in a broader perspective","volume":"5","author":"Oosterhuis","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0615","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41572-018-0029-0","article-title":"Testicular cancer","volume":"4","author":"Cheng","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/B978-0-12-816422-8.00008-8_bb0620","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.18.01480","article-title":"Serum levels of microRNA-371a-3p (M371 Test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study","volume":"37","author":"Dieckmann","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0625","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1016\/j.celrep.2018.05.039","article-title":"Integrated molecular characterization of testicular germ cell tumors","volume":"23","author":"Shen","year":"2018","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0630","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2217\/epi-2016-0081","article-title":"The epigenetics of testicular germ cell tumors: looking for novel disease biomarkers","volume":"9","author":"Costa","year":"2017","journal-title":"Epigenomics"},{"issue":"1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0635","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/cancers11010006","article-title":"The role of DNA\/histone modifying enzymes and chromatin remodeling complexes in testicular germ cell tumors","volume":"11","author":"Lobo","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0640","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1128\/MCB.00631-13","article-title":"LSD1 regulates pluripotency of embryonic stem\/carcinoma cells through histone deacetylase 1-mediated deacetylation of histone H4 at lysine 16","volume":"34","author":"Yin","year":"2014","journal-title":"Mol Cell Biol"},{"issue":"8","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0645","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.bmc.2018.01.031","article-title":"New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells","volume":"26","author":"Hoang","year":"2018","journal-title":"Bioorg Med Chem"},{"issue":"23","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0650","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1158\/0008-5472.CAN-11-0896","article-title":"Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties","volume":"71","author":"Wang","year":"2011","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0655","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00345-009-0498-6","article-title":"Deregulation of EZH2 expression in human spermatogenic disorders and testicular germ cell tumors","volume":"28","author":"Hinz","year":"2010","journal-title":"World J Urol"},{"issue":"8","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0660","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/sj.bjc.6605880","article-title":"Carcinoma in situ testis displays permissive chromatin modifications similar to immature foetal germ cells","volume":"103","author":"Almstrup","year":"2010","journal-title":"Br J Cancer"},{"issue":"21","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0665","doi-asserted-by":"crossref","first-page":"11295","DOI":"10.1073\/pnas.94.21.11295","article-title":"A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells","volume":"94","author":"Minucci","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0670","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1128\/MCB.22.13.4815-4826.2002","article-title":"JDP2, a repressor of AP-1, recruits a histone deacetylase 3 complex to inhibit the retinoic acid-induced differentiation of F9 cells","volume":"22","author":"Jin","year":"2002","journal-title":"Mol Cell Biol"},{"issue":"12","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0675","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/gcc.20918","article-title":"The seminoma cell line TCam-2 is sensitive to HDAC inhibitor depsipeptide but tolerates various other chemotherapeutic drugs and loss of NANOG expression","volume":"50","author":"Nettersheim","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"issue":"46","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0680","doi-asserted-by":"crossref","first-page":"74931","DOI":"10.18632\/oncotarget.11647","article-title":"A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment","volume":"7","author":"Nettersheim","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0685","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1158\/1535-7163.MCT-17-0293","article-title":"Animacroxam, a novel dual-mode compound targeting histone deacetylases and cytoskeletal integrity of testicular germ cell cancer cells","volume":"16","author":"Steinemann","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0690","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/jcmm.13059","article-title":"The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo","volume":"21","author":"Jostes","year":"2017","journal-title":"J Cell Mol Med"},{"issue":"7","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0695","doi-asserted-by":"crossref","first-page":"12484","DOI":"10.18632\/oncotarget.14226","article-title":"Epigenetic therapy in urologic cancers: an update on clinical trials","volume":"8","author":"Faleiro","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0700","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.pharmthera.2013.01.007","article-title":"Manipulating the epigenome for the treatment of urological malignancies","volume":"138","author":"O'Rourke","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0705","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3390\/ijms20061291","article-title":"Revisiting histone deacetylases in human tumorigenesis: the paradigm of urothelial bladder cancer","volume":"20","author":"Giannopoulou","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"37","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0710","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.2174\/0929867324666170207142740","article-title":"HDACs and HDAC inhibitors in urothelial carcinoma\u2014perspectives for an antineoplastic treatment","volume":"24","author":"Pinkerneil","year":"2017","journal-title":"Curr Med Chem"},{"key":"10.1016\/B978-0-12-816422-8.00008-8_bb0715","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13148-016-0264-8","article-title":"Epigenetic modulators as therapeutic targets in prostate cancer","volume":"8","author":"Graca","year":"2016","journal-title":"Clin Epigenetics"},{"issue":"4","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0720","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41585-019-0154-x","article-title":"Epigenetic drugs and their molecular targets in testicular germ cell tumours","volume":"16","author":"Jostes","year":"2019","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0725","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrneph.2016.168","article-title":"The epigenetic landscape of renal cancer","volume":"13","author":"Morris","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0730","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032750","article-title":"Integrated epigenome profiling of repressive histone modifications, DNA methylation and gene expression in normal and malignant urothelial cells","volume":"7","author":"Dudziec","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/B978-0-12-816422-8.00008-8_bb0735","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fgene.2012.00094","article-title":"The epigenetics of renal cell tumors: from biology to biomarkers","volume":"3","author":"Henrique","year":"2012","journal-title":"Front Genet"},{"issue":"2","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0740","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.canlet.2011.12.026","article-title":"Epigenetic biomarkers in urological tumors: a systematic review","volume":"342","author":"Jeronimo","year":"2014","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0745","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.1038\/s41467-018-07270-2","article-title":"Integrative epigenetic taxonomy of primary prostate cancer","volume":"9","author":"Stelloo","year":"2018","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/B978-0-12-816422-8.00008-8_bb0750","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.eururo.2011.06.035","article-title":"Epigenetics in prostate cancer: biologic and clinical relevance","volume":"60","author":"Jeronimo","year":"2011","journal-title":"Eur Urol"}],"container-title":["Histone Modifications in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128164228000088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128164228000088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T11:40:51Z","timestamp":1757677251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780128164228000088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128164228"],"references-count":149,"URL":"https:\/\/doi.org\/10.1016\/b978-0-12-816422-8.00008-8","relation":{},"subject":[],"published":{"date-parts":[[2020]]}}}